Optimi Health Announces Non-Brokered Private Placement
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer, has announced a non-brokered private placement of up to 16,666,666 units at CAD$0.30 per unit, aiming to raise up to CAD$5,000,000. Each unit consists of one common share and half a warrant, with each full warrant allowing the purchase of an additional share at CAD$0.40 for two years.
The company plans to use the proceeds for business development in Australia and globally, commissioning new equipment for GMP production and analytical laboratory, and general working capital. Insiders may participate for up to CAD$500,000. The offering includes an accelerated expiry provision and a potential 4% finder's fee for qualified non-related parties.
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN), un produttore di farmaci psichedelici approvato GMP e autorizzato da Health Canada, ha annunciato un collocamento privato non intermediato fino a 16.666.666 unità a 0,30 CAD per unità, con l'obiettivo di raccogliere fino a 5.000.000 CAD. Ogni unità è composta da un'azione ordinaria e mezza opzione, con ogni opzione completa che consente l'acquisto di un'azione aggiuntiva a 0,40 CAD per due anni.
L'azienda prevede di utilizzare i proventi per sviluppo commerciale in Australia e a livello globale, commissionando nuove attrezzature per la produzione GMP e un laboratorio analitico, oltre a capitale circolante generale. I membri interni possono partecipare per un massimo di 500.000 CAD. L'offerta include una clausola di scadenza accelerata e una potenziale commissione del 4% per gli intermediari qualificati non correlati.
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN), un fabricante de productos farmacéuticos psicodélicos aprobado por GMP y con licencia de Health Canada, ha anunciado un colocación privada no intermediada de hasta 16.666.666 unidades a 0,30 CAD por unidad, con el objetivo de recaudar hasta 5.000.000 CAD. Cada unidad consiste en una acción ordinaria y media garantía, siendo cada garantía completa que permite la compra de una acción adicional a 0,40 CAD durante dos años.
La empresa planea utilizar los ingresos para desarrollo comercial en Australia y a nivel mundial, encargando nuevos equipos para la producción GMP y un laboratorio analítico, así como para capital de trabajo general. Los miembros internos pueden participar hasta 500.000 CAD. La oferta incluye una cláusula de vencimiento acelerado y una posible tarifa de 4% para los intermediarios calificados no relacionados.
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN), GMP 승인 및 Health Canada 라이선스를 보유한 환각제 제약 제조업체가 중개인 없는 개인 배급 발표를 하였습니다. 이번 배급은 개당 0.30 CAD로 총 16,666,666 유닛을 목표로 하며, 최종 목표 금액은 5,000,000 CAD입니다. 각 유닛은 일반 주식 1주와 반 개의 워런트로 구성되며, 각 전체 워런트는 2년 동안 0.40 CAD로 추가 주식을 구매할 수 있습니다.
회사는 호주 및 전 세계에서의 사업 개발, GMP 생산 및 분석 연구소용 새로운 장비 구입, 일반 운영 자금 등에 수익금을 사용할 계획입니다. 내부자들은 최대 500,000 CAD까지 참여할 수 있습니다. 이번 제안에는 조기 만료 조항과 자격이 있는 비 관련 당사자를 위한 4% 중개 수수료의 가능성이 포함되어 있습니다.
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN), un fabricant de médicaments psychédéliques approuvé par le GMP et autorisé par Santé Canada, a annoncé un placement privé non intermédié pouvant aller jusqu'à 16 666 666 unités au prix de 0,30 CAD par unité, visant à lever jusqu'à 5 000 000 CAD. Chaque unité se compose d'une action ordinaire et d'une demi-option, chaque option entière permettant l'achat d'une action supplémentaire à 0,40 CAD pendant deux ans.
L'entreprise prévoit d'utiliser les fonds pour le développement des affaires en Australie et à l'international, la commande de nouveaux équipements pour la production GMP et les laboratoires d'analyse, ainsi que pour le fonds de roulement général. Les initiés peuvent participer jusqu'à 500 000 CAD. L'offre comprend une disposition d'expiration accélérée et une éventuelle commission de 4% pour les parties non liées qualifiées.
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN), ein GMP-zugelassener Hersteller von psychedelischen Arzneimitteln mit einer Lizenz von Health Canada, hat eine nicht vermittelte Privatplatzierung von bis zu 16.666.666 Einheiten zu je 0,30 CAD pro Einheit angekündigt, mit dem Ziel, bis zu 5.000.000 CAD zu sammeln. Jede Einheit besteht aus einer Stammaktie und einer halben Warrant, wobei jede vollständige Warrant den Kauf einer zusätzlichen Aktie zu 0,40 CAD für zwei Jahre ermöglicht.
Das Unternehmen plant, die Einnahmen für Geschäftsentwicklung in Australien und weltweit, die Anschaffung neuer Ausstattungen für die GMP-Produktion und ein analytisches Labor sowie für allgemeines Betriebskapital zu verwenden. Insidern wird die Teilnahme mit bis zu 500.000 CAD ermöglicht. Das Angebot umfasst eine beschleunigte Verfallsregelung und eine mögliche 4% Findergebühr für qualifizierte, nicht verwandte Parteien.
- Potential to raise up to CAD$5,000,000 in capital
- Expansion of business development opportunities in Australia and globally
- Investment in GMP production and analytical laboratory equipment
- Potential dilution of existing shareholders due to new share issuance
- Insider participation may raise concerns about conflicts of interest
Vancouver, British Columbia--(Newsfile Corp. - August 7, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, announces it intends to complete a non-brokered private placement of up to 16,666,666 units (each a "Unit") at CAD
Each Unit comprised of one (1) common share in the capital of the Company (each a "Common Share") and one-half of one (1/2) transferable Common Share purchase warrant (each whole warrant a "Warrant"). Each Warrant entitles the holder to acquire one (1) Common Share at CAD
It is anticipated that insiders of the Company may participate in the Offering for up to CAD
The Company intends to use the net proceeds from the Offering to further commercialize business development opportunities in Australia and around the world, commissioning recently purchased equipment for its GMP production and analytical laboratory, and general working capital. All securities issued under the Offering, including securities issuable on exercise thereof, will be subject to a hold period expiring 4 months and 1 day after issuance, in accordance with the rules and policies of the Exchange and applicable Canadian securities laws.
In connection with the Offering the Company may pay, to qualified non-related parties, a finder's fee in cash equal to
For more information, please contact:
OPTIMI HEALTH CORP.
Jacob Safarik, CFO
Telephone: (778) 897-3279
jacob@optimihealth.ca
For media inquiries, please contact:
Andrea Mestrovic
Andrea@weareverypolite.com
For investor inquiries, please contact:
Michael Kydd
investors@optimihealth.ca
For more information, please visit Optimi Health.
ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN)
Optimi is the only psychedelics pharmaceutical manufacturer in Canada with both a Controlled Drugs and Substances Dealer's Licence and a Drug Establishment Licence (DEL). Specializing in controlled substances such as botanical psilocybin and MDMA, Optimi is dedicated to supplying safe, top-tier GMP-grade products and API to researchers, drug developers, and authorized patients in markets across the world.
Optimi's leadership is reinforced by state-of-the-art, GMP-compliant cultivation, formulation, and analytical facilities, purpose-built to develop proprietary formulations that meet the highest standards of quality and responsible sourcing. Located in Princeton, British Columbia, the two facilities total 20,000 square feet where all products are grown and manufactured in-house under strict GACP and GMP conditions, ensuring unparalleled quality and reliability. The Company is committed to being the most trusted and compassionate supplier of safe psychedelic drug candidates worldwide.
FORWARD‐LOOKING STATEMENTS:
This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements") that relate to Optimi's current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. Forward-looking statements made in this news release include the proposed use of the proceeds of the Offering. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.
Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/219051
FAQ
What is the price per unit in Optimi Health's (OPTHF) private placement offering?
How much capital is Optimi Health (OPTHF) aiming to raise through this private placement?
What are the terms of the warrants included in Optimi Health's (OPTHF) offering?
How does Optimi Health (OPTHF) plan to use the proceeds from this private placement?
